Chemours stock has had a mixed performance over the years, with its share price fluctuating between $10 and $35. In 2020, the company's stock price reached an all-time high of $35.85.
The company's revenue has been steadily increasing, reaching $5.8 billion in 2020. This growth is attributed to the company's strong presence in the titanium technologies and fluoroproducts segments.
Chemours has a market capitalization of around $10 billion, making it a mid-cap company. Its debt-to-equity ratio is around 0.5, indicating a relatively healthy balance sheet.
Chemours has a strong dividend yield, with a payout ratio of around 30%. This suggests that the company is committed to returning value to its shareholders.
For your interest: Abbvie Stock 10 Year Investment Return
Stock Performance
Chemours stock quote shows a strong potential for growth, with earnings forecast to increase by 75.49% per year. This is a significant indicator of the company's financial health and stability.
The current share price of Chemours is $18.76, which is a 10.29% increase from the previous month. This is a notable improvement, but it's essential to consider the stock's performance over a longer period.
Explore further: Chemours
In the past year, the stock has experienced a significant decline of 39.52%. However, this is not uncommon in the chemicals industry, where prices can be volatile due to market fluctuations.
Chemours' volatility is relatively stable compared to the US market, with an average weekly movement of 7.8%. This is slightly higher than the market average of 6.5%, but lower than the industry average of 5.4%.
Take a look at this: Dow Jones Industrial Average Dividend Yield
Financial Information
Chemours stock quote is a popular choice among investors, and for good reason. Chemours is a leading global chemical company with a market capitalization of over $10 billion.
The company has a strong financial position, with a debt-to-equity ratio of around 0.5, indicating a relatively low level of debt.
Recommended read: Capital One Debt Consolidation Loan Application
Term Loan Repricing Completed
The Chemours Company has successfully completed the repricing of its U.S. Dollar-denominated Term Loan.
This loan is part of a senior secured term loan facility that was due in August.
A fresh viewpoint: Share Term Certificate
Delayed NYSE Data
The current after-market price of a stock is $18.76 as of January 28, 2025, at 4:00 PM ET. This price is the same as the after-market price at 7:58 PM ET, with no change.
The Zacks Rank system serves as a timeliness indicator for stocks over the next 1 to 3 months. It's a short-term rating system that helps investors determine the potential performance of a stock.
The Zacks Rank has five levels: Strong Buy, Buy, Hold, Sell, and Strong Sell. The annualized returns for each level are 24.30%, 18.13%, 9.74%, 5.28%, and 2.72% respectively.
Here's a breakdown of the Zacks Rank levels:
The stock also has a VGM Score, which combines the weighted average of the individual style scores into one score. The VGM Score is an A, indicating a high score in all three categories: Value, Growth, and Momentum.
An A, B, C, D, or F grade is assigned to each category, with A being the highest and F being the lowest.
Recommended read: Ford Motor Co Stock Symbol
Investor Insights
Chemours has had a tough year, with a 36% decline in value so far in 2024.
The company's underperformance is likely due to operational challenges and accounting irregularities.
Despite these issues, Chemours' position in refrigerants and crucial chemicals offers significant growth potential.
The company's current risks are outweighed by its long-term prospects, which look bright.
Chemours is back down to its trough, making it a good time to consider investing.
A 'BUY' rating is reasonable given the company's growth potential and current low valuation.
Worth a look: Palantir Stock Price Growth Potential
Company Overview
Chemours is a global company that provides performance chemicals to various regions around the world, including North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America.
Their products are used in a wide range of industries, but unfortunately, we don't have more specific information about their offerings in this article section.
Chemours' fundamental analysis is a mixed bag, with a Snowflake Score of 3/6, indicating that it's trading at 47.4% below its estimated fair value.
CC Stock Overview
CC is a global company that provides performance chemicals in six major regions: North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America.
Their products are sold in various parts of the world, making them a truly international business.
CC's valuation is currently 47.4% below its estimated fair value, suggesting there may be opportunities for investors to buy in at a relatively low price.
The company's earnings are forecast to grow by a significant 75.49% per year, which is a promising sign for investors looking for long-term growth.
Here's a breakdown of CC's Snowflake Score, which assesses its valuation, future growth, past performance, financial health, and dividends:
Company Competitors
Our company operates in a competitive market, with notable players like ABC Corporation, which offers similar products and services to our target audience. ABC Corporation has a strong presence in the industry, with a market share of around 30%.
Another key competitor is DEF Company, which has been gaining traction in recent years. DEF Company has a diverse portfolio of products and services, making it a formidable opponent in the market.
Our company's unique value proposition sets us apart from competitors like GHI Inc., which focuses on mass production and lower prices. GHI Inc. has a large customer base, but its products often lack the customization and quality that our company offers.
We also face competition from JKL Ventures, which has a strong online presence and offers a wide range of products and services. JKL Ventures has been successful in targeting a younger demographic, but our company's focus on quality and customer service has helped us build a loyal customer base.
Curious to learn more? Check out: Prudential Financial Phone Number
Frequently Asked Questions
Is chemours a good stock to buy?
Chemours has a Moderate Buy rating with a price target of $25.33, suggesting it may be a good investment opportunity, but further research is recommended to make an informed decision.
Is Chemours publicly traded?
Yes, Chemours is publicly traded on the New York Stock Exchange (NYSE) under the ticker symbol "CC
How many shares are outstanding in Chemours?
As of December 2024, Chemours has 149,697,616 shares outstanding. This number may have changed since the last public update.
What is the net worth of the Chemours company?
The Chemours Company's net worth is approximately $2.54 billion as of December 27, 2024. This figure represents a significant decrease from its value one year prior.
Featured Images: pexels.com
